Skip To Main Content
Anna Yang on Muck Rack

Anna Yang

As seen in: Spoon University, Illumination, Medium, The New York Times, Wiley Online Library, MDPI, ACS Publications, BioRxiv, Cell Press, MedCity News, NewsBreak and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anna

Contact Anna, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Limiting antihypertensive use does not reduce mortality in nursing home residents with frailty

|
By Anna Yang
| 2 Minute Medicine Verified
1. In this randomized clinical trial, among older nursing home residents with frailty who were being treated for hypertension with at least two antihypertensive agents, an antihypertensive medication step-down strategy was not found to have a significant effect on all-cause mortality. 2. Secondary outcomes, including major adverse cardiovascular events and measures of functional capacity, were also similar between the two groups.
Open in Who Shared Issue with article?

Presymptomatic treatment of spinal muscular atrophy with risdiplam leads to improved functional outcomes

|
By Anna Yang
| 2 Minute Medicine Verified
1. In this single-group trial, among infants predicted to develop type 1 spinal muscular atrophy (SMA) who were treated presymptomatically with risdiplam within the first six weeks after birth, most had the ability to sit up within 12 months, which would not be possible for most untreated infants. 2. These infants also survived without assisted ventilation and achieved appropriate motor milestones over a period of 24 months, which would not be attainable with supportive care alone.
Open in Who Shared Issue with article?

Ciprofloxacin is non-inferior to aminoglycoside-ciprofloxacin for bubonic plague treatment

|
By Anna Yang
| 2 Minute Medicine Verified
1. In this randomized controlled trial, among patients with bubonic plague, oral ciprofloxacin monotherapy was found to be noninferior to sequential treatment with an injectable aminoglycoside followed by oral ciprofloxacin with respect to incidence of treatment failure. 2. The percentages of patients with a serious adverse event or nonserious adverse event were similar between the two groups.
Open in Who Shared Issue with article?
See all 93 licensed articles (101 Total)